Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines


ARI F. , Napieralski R., Ulukaya E.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.38, no.2, pp.154-162, 2013 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.5505/tjb.2013.46320
  • Title of Journal : TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Page Numbers: pp.154-162
  • Keywords: DNA methylation, breast cancer, apoptosis, decitabine, FEC, O-6-METHYLGUANINE DNA METHYLTRANSFERASE, PROMOTER HYPERMETHYLATION, PROTEIN-KINASE, CLINICAL-SIGNIFICANCE, LUMINESCENCE ASSAY, REPAIR GENES, SERUM DNA, EXPRESSION, TUMOR, DEMETHYLATION

Abstract

Objective: Epigenetic modulation of gene expression by DNA promoter methylation may contribute to acquired resistance to chemotherapy in cancer cells. Decitabine (5-aza-2'-deoxycytidine), a demethylating agent, may act synergistically with standard chemotherapy regimens to activate epigenetically silenced genes. In the present in vitro study, it was investigated the effect of gene methylation level after treatment with decitabine and combination of decitabine with anthracycline-based therapeutics (5-fluorouracil plus epirubicine plus cyclophosphamide; FEC) on breast cancer cells (MCF-7 and MDA-MB-231).